Woodline Partners’s Cogent Biosciences COGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$64.1M Sell
2,000,498
-602,664
-23% -$22.3M 0.19% 118
2026
Q2
$101M Buy
2,603,162
+1,093,605
+72% +$38.3M 0.31% 70
2026
Q1
$58.1M Buy
1,509,557
+690,775
+84% +$25.5M 0.22% 113
2025
Q4
$29.1M Buy
818,782
+305,385
+59% +$8.58M 0.11% 236
2025
Q3
$7.37M Sell
513,397
-487,214
-49% -$5.77M 0.03% 497
2025
Q2
$7.18M Sell
1,000,611
-686,929
-41% -$3.81M 0.04% 492
2025
Q1
$10.1M Buy
1,687,540
+1,074,375
+175% +$8.42M 0.07% 360
2024
Q4
$4.78M Buy
613,165
+12,589
+2% +$125K 0.03% 494
2024
Q3
$6.49M Buy
600,576
+478
+0.1% +$4.65K 0.05% 358
2024
Q2
$5.06M Sell
600,098
-98,280
-14% -$745K 0.05% 338
2024
Q1
$4.69M Sell
698,378
-92,106
-12% -$569K 0.04% 368
2023
Q4
$4.65M Buy
790,484
+670,484
+559% +$5.14M 0.05% 326
2023
Q3
$1.17M Buy
+120,000
New +$1.42M 0.01% 434
2022
Q4
– Sell
-69,871
Closed -$1.04M – 769
2022
Q3
$1.04M Buy
+69,871
New +$958K 0.01% 530
2022
Q2
– Sell
-36,783
Closed -$276K – 812
2022
Q1
$276K Buy
+36,783
New +$256K ﹤0.01% 536

Other funds holding COGT

Woodline Partners's COGT Position: Q3 2026 in Review

Woodline Partners reduced its Cogent Biosciences (COGT) stake by 23% in Q3 2026, selling an estimated $22.3M and leaving 2,000,498 shares worth $64.1M. The position accounts for 0.19% of the portfolio, ranked #118.

Woodline Partners first reported a position in COGT in Q1 2022 and has held it in 15 quarters since. The position peaked at $101M in Q2 2026. 208 funds tracked by Wall St. Rank hold COGT as of Q3 2026.

  • Woodline Partners held 2,000,498 shares of Cogent Biosciences worth $64.1M as of Q3 2026.
  • Woodline Partners sold 602,664 Cogent Biosciences shares in Q3 2026, an estimated $22.3M.
  • Cogent Biosciences made up 0.19% of Woodline Partners's portfolio in Q3 2026, its #118 holding.
  • Woodline Partners first reported a position in Cogent Biosciences in Q1 2022 and has held it in 15 quarters since.
  • Woodline Partners's Cogent Biosciences position peaked at $101M in Q2 2026.
  • 208 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2026.

Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.